Increased FOXM1 levels in Luminal subtype BC patients receiving chemotherapy or tamoxifen are associated with poorer outcomes, suggesting a link to treatment resistance or noncompliance [27,46,47]. This evidence concerns the gene FOXM1 and breast cancer.